Translational Sciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Strategy for Improving Stroke Treatment Response
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Translational Sciences, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05948566
- Locations
- 🇺🇸
University of Louisville Hospital, Louisville, Kentucky, United States
🇺🇸Providence St. Vincent Medical Center, Portland, Oregon, United States
🇺🇸Ascension Columbia St. Mary's Hospital, Milwaukee, Wisconsin, United States
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Translational Sciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05408546
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer
Phase 1
- Conditions
- Cerebral IschemiaMyocardial InfarctionThrombosisVenous ThrombosisPulmonary Embolism
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2016-12-23
- Lead Sponsor
- Translational Sciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03001544
News
No news found